Sage Journals: Discover world-class research

Abstract

This article argues that correctional institutions violate the Eighth Amendment when they refuse to establish MAT programs and prevent doctors from exercising medical judgment to properly treat incarcerated people with OUD.

Get full access to this article

View all access options for this article.

References

The Sentencing Project, “Fact Sheet: Trends in U.S. Corrections,” June 26, 2017, available at <https://www.sentencing-project.org/publications/trends-in-u-s-corrections/> (last visited April 6, 2018).

Ingraham

, “CDC Releases Grim New Opioid Overdose Figures: ‘We’re Talking about More than an Exponential Increase,’” Washington Post, December 21, 2017, available at <https://www.washingtonpost.com/news/wonk/wp/2017/12/21/cdc-releases-grim-new-opioid-overdose-figures-were-talking-about-more-than-an-exponential-increase/?utm_term=.607955741560> (last visited April 6, 2018).

Bronson

et al ., Bureau of Justice Statistics, Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007-2009, NCJ 250546 (June 2017).

See Section III. infra.

American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (Arlington, VA: American Psychiatric Association Publishing, 2013).

Williams

, “Opioid Users Are Filling Jails. Why Don’t Jails Treat Them?” New York Times, August 4, 2017, available at <https://www.nytimes.com/2017/08/04/us/heroin-addiction-jails-methadone-suboxone-treatment.html> (last visited April 6, 2018).

Center for Substance Abuse Treatment, Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs, Treatment Improvement Protocol Series 43 (Revised 2012).

T.W.

Park and

P.D.

Friedmann , “Medication for Addiction Treatment: An Opportunity for Prescribing Clinicians to Facilitates Remission from Alcohol and Opioid Use Disorders,” Rhode Island Medical Journal 97, no. 10 (2014): 20-24, at 22-23.

Williams, supra note 6; see also

P.D.

Friedmann

et al ., “Medication-Assisted Treatment in Criminal Justice Agencies Affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, Barriers & Intentions,” Substance Abuse 33 (2012): 9-18, at 12; A. Nunn et al., “Metha-done and Buprenorphine Prescribing and Referral Practices in US Prison Systems: Results from a Nationwide Survey,” Drug and Alcohol Dependence 105 (2009): 83-88, at 84-85; B. Schwartzapfel, “A Better Way to Treat Addiction in Jail,” The Marshall Project, March 1, 2017, available at <https://www.themarshallproject.org/2017/03/01/a-better-way-to-treat-addiction-in-jail> (last visited April 6, 2018).

10.

R.K.

Chandler

et al ., “Treating Drug Abuse and Addiction in the Criminal Justice System: Improving Public Health and Safety,” JAMA 301 (2009): 183-190, at 185.

11.

Greene

et al ., “Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System,” JAMA Psychiatry (February 14, 2018): E1-E3, at E1, available at <https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2671411> (last visited April 6, 2018).

12.

See Section IV.

13.

For an excellent overview of the topic, see

Lebowitz

, “‘Proper Subjects for Medical Treatment?’ Addiction, Prison-Based Drug Treatment, and the Eighth Amendment,” DePaul Journal of Healthcare Law 14, no. 2 (2012): 271-308.

14.

.S. Constitution, amendment VIII.

15.

Estelle v. Gamble, 429 U.S. 97, 103 (1976).

16.

Id., at 99.

17.

Id., at 100.

18.

Id.

19.

Id., at 100-01.

20.

Id., at 104.

21.

Id.

22.

Id., at 105.

23.

Id., at 106

24.

Madrid v. Gomez, 889 F. Supp. 1146, 1210 (N.D. Cal. 1995).

25.

Id., at 1215.

26.

Coleman v. Wilson, 912 F. Supp. 1282, 1316, 1319 (E.D. Cal. 1995).

27.

Brown v. Plata, 563 U.S. 493, 500 (2011).

28.

Id. at 502.

29.

Plata, 563 U.S. at 511.

30.

Wellman v. Faulkner, 715 F.2d 269, 272 (7th Cir. 1983) (internal citations omitted).

31.

Braggs v. Dunn, 257 F. Supp. 3d 1171, 1267 (M.D. Ala. 2017).

32.

Dunn v. Dunn, 219 F. Supp. 3d 1100, 1123 (M.D. Ala. 2016).

33.

See e.g., Postawko v. Mo. Dep’t Corr., 2017 U.S. Dist. LEXIS 117238, at *51 (W.D. Mo.); Lipert v. Baldwin, 2017 U.S. Dist. LEXIS 64687, at *28 (N.D. Ill.).

34.

Hoffer v. Jones, 2017 U.S. Dist. LEXIS 194544, at *6 (N.D. Fla.).

35.

Wilson v. Seiter, 501 U.S. 294, 300 (1991).

36.

Farmer v. Brennan, 511 U.S. 825, 847 (1994).

37.

Seiter, 501 U.S. at 297.

38.

Farmer, 511 U.S. at 836, 839-40.

39.

Id., at 842.

40.

Baez v. Rogers, 522 Fed. Appx. 819, 821 (11th Cir. 2013) (citing McElligott v. Foley, 182 F.3d 1248, 1255 (11th Cir. 1999)).

41.

Farmer, 511 U.S. at 844.

42.

Jones v. Bradshaw, 2017 U.S. Dist. LEXIS 46829, at *26-27 (S.D. Fla.).

43.

Bowring v. Godwin, 551 F.2d 44, 48 (4th Cir. 1977).

44.

Tarver v. McLaughlin, 2017 U.S. Dist. LEXIS 129737, at *12 (M.D. Ga.).

45.

Corley v. Wexford Health Sources, Inc., 2016 U.S. Dist. LEXIS 122306, at *31 (S.D. Ill.).

46.

Knop v. Johnson, 667 F.Supp. 512, 528 (W.D. Mich. 1987).

47.

Prosser v. Nagaldinne, 927 F. Supp. 2d 708, 728 (E.D. Mo. 2013).

48.

King v. Kramer, 680 F.3d 1013, 1019 (7th Cir. 2012).

49.

McGiboney v. CCA Western Props., 2016 U.S. Dist. LEXIS 27491, at *23-24 (D. Idaho).

50.

Hoptowit v. Ray, 682 F.2d 1237, 1253 (9th Cir. 1982).

51.

Waldrop v. Evans, 871 F.2d 1030, 1035 (11th Cir. 1989).

52.

United States v. DeCologero, 821 F.2d 39, 43 (1st Cir. 1987).

53.

Nauroth v. Southern Health Partners, Inc., 2009 U.S. Dist. LEXIS *86467, at *33 (S.D. Ohio).

54.

Butler v. City of Pontiac, 2006 U.S. Dist. LEXIS 55845, at *18 (E.D. Mich.).

55.

Harris v. Thigpen, 941 F.2d 1495, 1509 (11th Cir. 1991).

56.

Dunn v. Dunn, 219 F. Supp. 3d at 1130.

57.

Estelle, 429 U.S. at 104.

58.

Helling v. McKinney, 509 U.S. 25, 27-28 (1993).

59.

McKinney v. Anderson, 924 F.2d 1500, 1505-09 (9th Cir. 1991), vacated, 502 U.S. 903 (1991).

60.

Helling, 509 U.S. at 30, 33.

61.

Id., at 33.

62.

Id., at 36.

63.

See Wakefield v. Thomas, 777 F.3d 1160 (9th Cir. 1999); Lugo v. Senkowski, 114 F. Supp. 2d 111 (N.D.N.Y. 2000).

64.

Gaudreault v. Municipality of Salem, Mass., 923 F.2d 203, 208 (1st Cir. 1990) (citing Laaman v, Helgemoe, 437 F. Supp. 269, 311(D.N.H. 1977)); Monmouth Cnty. Corr. Institutional Inmates v. Lanzaro, 834 F.2d 326, 347 (3d Cir. 1987); Gutierrez v. Peters, 111 F.3d 1364, 1373 (7th Cir. 1997); Sheldon v. Pezley, 49 F.3d 1312, 1316 (8th Cir. 1995); Ramos v. Lamm, 639 F.2d 559, 575 (10th Cir. 1980); Hill v. Dekalb Reg’l Youth Det. Ctr., 40 F.3d 1176, 1187 (11th Cir. 1994).

65.

Brock v. Wright, 315 F.3d 158, 162 (2d Cir. 2003) (quoting Chance v. Armstrong, 143 F.3d 698, 702 (2d Cir. 1998)). See also McGuckin v. Smith, 974 F.2d 1050, 1059-60 (9th Cir. 1992), overruled in part on other grounds by WMX Techs., Inc. v. Miller, 104 F.3d 1133, 1135 (9th Cir. 1997).

66.

W.J. Rold, “Thirty Years After Estelle v. Gamble: A Legal Retrospective,” Journal of Correctional Health Care 14 (2008): 11-20, at 16.

67.

Davis v. Carter, 452 F.3d 686, 689-90 (7th Cir. 2006); Demouchette v. Dart, 2015 U.S. Dist. LEXIS 18582, at *11 (N.D. Ill.); Idyle v. N.C. Dep’t of Corr. Med. Dep’t, 2014 U.S. Dist. LEXIS 13765, at *6 (E.D.N.C.); Meiller v. Pasco County, 2010 U.S. Dist. LEXIS 140523, at *26-27 (M.D. Fla.); Alvarado v. Westchester County, 22 F. Supp. 3d 208, 217 (S.D.N.Y. 2014); Sylvester v. City of Newark, 120 Fed. Appx. 419, 423 (3d Cir. 2005); Quatroy v. Jefferson Parish Sheriff ’s Office, 2009 U.S. Dist. LEXIS 40807, at *27-28 (E.D. L.A.); Gonzalez v. Cecil County, 221 F. Supp. 2d 611, 616 (D. Md. 2002); Butler, 2006 U.S. Dist. LEXIS 55845 at *17-18.

68.

See e.g., Iacovangelo v. Corr. Med. Care, Inc., 624 Fed. Appx. 10, 13 (2d Cir. 2015); Shaver v. Brimfield Twp., 2014 U.S. Dist. LEXIS 180571, at *41 (N.D. Ohio).

69.

United States ex rel. Walker v. Fayette County, 599 F.2d 573, 576 (3d Cir. 1979).

70.

Demouchette, 2015 U.S. Dist. LEXIS 18582 at *13.

71.

Quatroy, 2009 U.S. Dist. LEXIS 40807 at *5.

72.

Messina v. Mazzeo, 854 F. Supp. 116, 140 (E.D.N.Y. 1994).

73.

Helling, 509 U.S. at 36.

74.

N.D.

Volkow , National Institute on Drug Abuse, Drugs, Brains, and Behavior: The Science of Addiction, NIH Pub. No. 14-5605 (revised July 2014): at 5.

75.

D.S.

Hasin

et al ., “DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale,” American Journal of Psychiatry 170 (2013): 835-851, at 836.

76.

Jessell

et al ., “Sexual Violence in the Context of Drug Use Among Young Adult Opioid Users in New York City,” Journal of Interpersonal Violence 32 (2015): 2929-2954, at 2931.

77.

R.K.

Brooner

et al ., “Psychiatric and Substance use Comorbidity Among Treatment-Seeking Opioid Abusers,” Archives of General Psychiatry 54 (1997): 71-80, at 74.

78.

Winklbaur

et al ., “Treating Pregnant Women Dependent on Opioids is not the Same as Treating Pregnancy and Opioid Dependence: A Knowledge Synthesis for Better Treatment for Women and Neonates,” Addiction 103 (2008): 1429-1440, at 1429-30.

79.

M.V.

Ronan

et al ., “Hospitalizations Related to Opioid Abuse/Dependence and Associated Serious Infections from 2002 to 2012,” Health Affairs 35 (2016): 832-837, at 836.

80.

Teesson

et al ., “Long-Term Mortality, Remission, Criminality and Psychiatric Comorbidity of Heroin Dependence: 11-year Findings from the Australian Treatment Outcome Study,” Addiction 110 (2015): 986-993, at 991.

81.

M.A.

Schuckit

, “Treatment of Opioid Use Disorders,” N. Engl. J. Med. 375 (2016): 357-268, at 357.

82.

Connock

et al ., “Methadone and Buprenorphine for the Management of Opioid Dependence: A Systematic Review and Economic Evaluation,” Health Technology Assessment 11, no. 9 (2007): 1-6, at 3.

83.

B.A.

Moore

et al ., “Primary Care Office-Based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients,” Journal of General Internal Medicine 22 (2007): 527-30.

84.

R.D.

Weiss

et al ., “Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence,” Archives of General Psychiatry 68, (2011): 1238-46, at 1243.

85.

Id .

86.

See e.g.,

Farré

et al ., “Retention Rate and Illicit Opioid use During Methadone Maintenance Interventions: A Meta-Analysis,” Drug and Alcohol Dependence 65 (2002): 283-290, at 286.

87.

See e.g.,

G.E.

Woody

et al ., “Extended vs. Short-Term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth: A Randomized Trial,” JAMA 300 (2008): 2003-2011; D.A. Fiellin et al., “Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence” NEJM 355 (2006): 365-374; L.A. Marsch, “The Efficacy of Methadone Maintenance Interventions in Reducing Illicit Opiate Use, HIV Risk Behavior and Criminality: A Meta-Analysis,” Addiction 93 (1998): 515-532, at 515.

88.

M.F.

Raleigh

, “Buprenorphine Maintenance vs. Placebo for Opioid Dependence, American Family Physician 95 (2017): 290-291, at 290.

89.

Arroll

et al ., “Efficacy and Tolerability of Tricyclic Antidepressants and SSRIs Compared With Placebo for Treatment of Depression in Primary Care: A Meta-Analysis,” Annals of Family Medicine 3 (2005): 449-456, at 449.

90.

D.E.

Jonas

et al ., “Pharmacotherapy for Adults with Alcohol use Disorders in Outpatient Settings: A Systematic Review and Meta-Analysis,” JAMA 311 (2014): 1889-1900, at 1892.

91.

Kooy

et al ., “Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus,” Archives of Internal Medicine 169 (2009): 615-626, at 620; J.J. Mourad et al., “Number Needed to Treat and Reduction of Outcomes with RAAS Inhibitors,” European Heart Journal 34 (2013): 1117-1118, at 1117.

92.

J.D.

Lee

et al ., “Opioid Treatment at Release from Jail using Extended Release Naltrexone: A Pilot Proof-of-Concept Randomized Effectiveness Trial,” Addiction 110 (2015): 1008-1014, at 1009.

93.

Kunøe

et al , “Design of a Randomized Controlled Trial of Extended-Release Naltrexone Versus Daily Buprenorphine-Naloxone for Opioid Dependence in Norway (NTX-SBX)” BMC Pharmacology & Toxicology 17, no. 18 (2016): 1-10.

94.

S.J.

Cousins

et al ., “Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County,” Journal of Substance Abuse Treatment 63 (2016): 66-71.

95.

Bronson, supra note 3.

96.

V.S.

Westerberg

et al ., “Community-Based Methadone Maintenance in a Large Detention Center is Associated with Decreases in Inmate Recidivism,” Journal of Substance Abuse Treatment 70 (2016): 1-6, at 1.

97.

J.G.

Clarke

et al ., “Active and Former Injection Drug Users Report of HIV Risk Behaviors During periods of Incarceration,” Substance Abuse 22 (2001): 209-216, at 213.

98.

See note 9, supra.

99.

Schuckit, supra note 81, at 357.

100.

M.E.

Noonan

, Bureau of Justice Statistics, Mortality in Local Jails, 2000-2014 – Statistical Tables, NCJ 250169 (December 2016): 6; Pamela Lehman, “Jail Staff Trained to Use Narcan to Prevent Opioid Overdoses,” Morning Call, September 18, 2017, available at <http://www.mcall.com/news/breaking/mc-nws-narcan-jails-20170811-story.html> (last visited April 6, 2018).

101.

Noonan, supra note 100, at 6.

102.

M.E.

Noonan

, Bureau of Justice Statistics, Mortality in States Prisons, 2001-2014 – Statistical Tables, NCJ 250150 (December 2016): 5.

103.

See e.g.,

Johnson

, “State Officials Calls Prevalence of Drugs in Prisons, Regional Jails ‘Disgraceful,” MetroNews, March 16, 2017, available at <http://wvmetronews.com/2017/03/16/state-official-calls-prevalence-of-drugs-in-prisons-regional-jails-disgraceful> (last visited April 6, 2018); Associated Press, “California Inmates Dying of Drug Overdoses at Rate Nearly Triple the National Average,” Fox News, June 21, 2015, available at <http://www.foxnews.com/us/2015/06/21/california-inmates-die-drug-overdoses-at-rate-nearly-triple-national-average.html> (last visited April 6, 2018); J. Hernandez, “Recent Overdoses Highlight the Difficulty of Keeping Drugs out of Jail,” WHYY, Oct. 16, 2017, available at <https://whyy.org/articles/recent-south-jersey-overdoses-highlight-difficulty-keeping-drugs-jails> (last visited April 6, 2018); S. Houser, “Marion County Sheriff’s Office Warns of Increase in Drug Overdoses Inside Jail,” Fox 59, Aug. 30, 2017, available at <http://fox59.com/2017/08/30/marion-county-sheriffs-office-warns-of-increase-in-drug-overdoses-inside-jail> (last visited April 6, 2018).

104.

Centers for Disease Control and Prevention, National Center for Health Statistics, “Underlying Cause of Death 1999-2016 on CDC WONDER Online Database,” released December, 2017, available at <http://wonder.cdc.gov/ucd-icd10.html> (last visited April 6, 2018).

105.

E.L.C.

Merrall

et al ., “Meta-Analysis of Drug-Related Deaths Soon after Release from Prison,” Addiction 105 (2010): 1545-1554, at 1549.

106.

Id .

107.

I.A.

Binswanger

et al ., “Mortality After Prison Release: Opioid Overdose and Other Causes of Death, Risk Factors, and Time Trends from 1999-2009,” Annals of Internal Medicine 159 (2013): 592-600, at 597.

108.

J.D.

Rich

et al ., “Methadone Continuation Versus Forced Withdrawal on Incarceration in a Combined US Prison and Jail: A Randomized, Open-Label Trial,” Lancet 386 (2015): 350-59, at 351-52, 355-56.

109.

Gisev

et al ., “Determining the Impact of Opioid Substitution Therapy upon Mortality and Recidivism among Prisoners: A 22 Year Data Linkage Study,” Technical Report no. 330 (2014): 34.

110.

Marsden

et al ., “Does Exposure to Opioid Substitution Treatment in Prison Reduce the Risk of Death after Release? A National Prospective Observational Study in England,” Addiction 112 (2017): 1408-1418, at 1415.

111.

Clarke et al., supra note 97, at 216.

112.

Helling, 509 U.S. at 33.

113.

Plata, 563 U.S. at 509, 531-32.

114.

A.L.

Beckman

et al ., “New Hepatitis C Drugs Are Very Costly And Unavailable to Many State Prisoners,” Health Affairs 35 (2016): 1893-1901, at 1893.; K. Stark et al., “History of Syringe Sharing in Prison, and Risk of Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus Infection among Injecting Drug Users in Berlin,” International Journal of Epidemiology 26 (1997): 1359-1366, at 1363.

115.

Beckman et al., supra note 114, at 1893.

116.

Scutti

, “New Hepatitis C Infections Triple Due to Opioid Epidemic,” CNN, May 11, 2017, available at <http://www.cnn.com/2017/05/11/health/hepatitis-c-rates-cdc-study/index.html> (last visited April 6, 2018).

117.

Beckman, supra note 114, at 1893.

118.

N.A.

Bretaña

et al ., “Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012,” Emerging Infections Diseases 21 (2015): 765-774, at 770.

119.

S.A.

Springer

et al ., “Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment,” Journal of Urban Health 87 (2010): 592-602, at 592, 598.

120.

Dolan

et al ., “People who Inject Drugs in Prison: HIV Prevalence, Transmission and Prevention,” International Journal of Drug Policy 26 (2015): 512-515, at 513.

121.

Helling, 509 U.S. at 35.

122.

Fullerton

et al ., “Medication-Assisted Treatment With Metha-done: Assessing the Evidence,” Psychiatric Services 65 (2014): 146-157, at 153.

123.

Marsch, supra note 87, at 515.

124.

Gowing

et al ., “Substitution Treatment of Injecting Opioid Users for Prevention of HIV Infection,” Cochrane Database of Systematic Reviews 2 (2008): 1-52, at 15-16.

125.

K.A.

Dolan

et al ., “Four-Year Follow-Up of Imprisoned Male Heroin Users and Methadone Treatment: Mortality, Re-Incarceration and Hepatitis C Infection,” Addiction 100 (2005): 820-28, at 824.

126.

Beckman, supra note 114, at 1899.

127.

Goodnough and

Zernike , “Seizing on Opioid Crisis, a Drug Maker Lobbies Hard for Its Product,” New York Times, June 11, 2017, available at <https://www.nytimes.com/2017/06/11/health/vivitrol-drug-opioid-addiction.html> (last visited April 6, 2018).

128.

Substance Abuse and Mental Health Services Administration, State Targeted Response to the Opioid Crisis Grants, T1-17-014, available at <https://www.samhsa.gov/sites/default/files/grants/pdf/other/ti-17-014-opioid-str-abstracts.pdf> (last visited April 6, 2018)..

129.

Substance Abuse and Mental Health Services Administration, “Certification of Opioid Treatment Programs,” available at <https://www.samhsa.gov/medication-assisted-treatment/opioid-treatment-programs> (last visited April 6, 2018).

130.

Monmouth County Correctional Institutional Inmates v. Lanzaro, 834 F.2d 326 (3d Cir. 1987).

131.

H.E.

Jones

, “Practical Considerations for the Clinical Use of Buprenorphine,” Science and Practice Perspectives 2, no. 2 (2004): 4-20, at 9.

132.

Reynaud

et al ., “Six Deaths Linked to Concomitant use of Buprenorphine and Benzodiazepines,” Addiction 93 (1998): 1385-1392, at 1389.

133.

Lavender

, “California Prisons Aim to Keep Sex Between Inmates Safe, If Illegal,” NPR, January 21, 2015, available at <https://www.npr.org/2015/01/21/378678167/california-prisons-aim-to-keep-sex-between-inmates-safe-if-illegal> (last visited April 6, 2018).

134.

Lebowitz, supra note 13, at 297 n.144.

135.

Brown, 563 U.S. at 511.

136.

Nunn et al., supra note 9, at 86.

137.

Dunn v. Dunn, 219 F. Supp. 3d at 1127. See also Baez, 522 F. Appx. at 821.

138.

Sain v. Wood, 512 F.3d 886, 895 (7th Cir. 2008).

139.

Inmates of Allegheny County Jail v. Pierce, 612 F.2d 754, 762 (3rd Cir. 1979)

140.

Hoptowit, 682 F.2d at 1253.

141.

Id .

142.

Harris, 941 F.2d at 1509.

143.

Hoffer 2017 U.S. Dist. LEXIS 194544, at *6.

144.

Harris, 941 F.2d at 1509.

145.

P.A.

Donaher and

Welsh , “Managing Opioid Addiction with Buprenorphine,” American Family Physician 73 (2006): 1573-1578, at 1577.

146.

J.D.

Rich

et al ., “Linkage with Methadone Treatment Upon Release from Incarceration,” Journal of Addictive Diseases 24 (2005): 49-59, at 56.

147.

Magura

et al ., “Buprenorphine and Methadone Maintenance in Jail and Post-Release: A Randomized Clinical Trial,” Drug and Alcohol Dependence 99 (2009): 222-230, at 227.

148.

Id. at 228.

149.

M.S.

Gordon

et al ., “A Randomized Controlled Trial of Prison-Initiated Buprenorphine: Prison Outcomes and Community Treatment Entry,” Drug and Alcohol Dependence 142 (2014): 33-40, at 38.

150.

J.T.

Lin and

Matthew , “Cancer Pain Management in Prisons: A Survey of Primary Care Practitioners and Inmates,” Journal of Pain and Symptom Management 29 (2005): 466-473, at 471-472.

151.

Freyer

, “R.I. Prison Takes a Leap into Comprehensive Addiction Care,” The Boston Globe, August 14, 2017, available at <https://www.bostonglobe.com/metro/2017/08/13/prison-takes-leap-into-comprehensive-addiction-care/K3lxG2FPWsI7mmwqMOSXxN/story.html> (last visited April 6, 2018); K.F. Maurer, “Opioid Addiction and Corrections: Medication Assisted Treatment in the Connecticut Department of Correction,” April 30, 2015, available at <http://www.ct.gov/opm/lib/opm/cjppd/cjcjpac/20150430_cjpacpowerpoint_-metha-done_presentation.pdf> (last visited April 6, 2018).

152.

Farabee

et al ., “Treatment in Criminal Justice Settings,” in

el-Guebaly

et al ., eds., Textbook of Addiction Treatment: International Perspectives (Milano: Springer-Verlag Mailand, 2015): 1129-1144, at 1134-1135.

153.

Weiss et al., supra note 84, at 1244.

154.

Fiellin et al., supra note 87, at 371;

R.P.

Schwartz

et al ., “Randomized Trial of Standard Methadone Treatment Compared to Initiating Methadone without Counseling: 12-month Findings,” Addiction 107 (2012): 943-952, at 950.

155.

P.D.

Friedmann and

R.P.

Schwartz , “Just Call it ‘Treatment,’” Addiction Science & Clinical Practice 7, no. 10 (2012): 1-3, at 2.

156.

Helling, 509 U.S. at 36.

157.

Rhodes v. Champan, 452 U.S. 337, 346 (1981) (quoting Trop v. Dulles, 356 U.S. 86, 101 (1958) (plurality opinion)).

158.

D. Lebowitz, supra note 13, at 297-298.

159.

Dunn, 219 F. Supp. 3d at 1128 n.37.

160.

See

D.E.

Smith

, “The Evolution of Addiction Medicine as a Medical Specialty,” American Medical Association Journal of Ethics 13 (2011): 900-905, at 902-903.

161.

World Health Organization, “Principles of Drug Dependence Treatment,” (March 2008), available at <http://www.who.int/substance_abuse/publications/principles_drug_dependence_treatment.pdf>(last visited April 6, 2018).

162.

National Institute of Drug Abuse, Principles of Drug Addiction Treatment, Pub. No 12-4180 (revised December 2012).

163.

Center for Substance Abuse Treatment, supra note 7.

164.

Center for Disease Control, “Treat Opioid Use Disorder”, available at <https://www.cdc.gov/drugoverdose/prevention/treatment.html> (last visited April 6, 2018).

165.

Combating the Opioid Abuse Epidemic: Professional and Academic Perspectives: Hearing Before the H. Comm. on Energy and Commerce, 114th Cong. (2015) (Statement of the American Medical Association).

166.

American Academy of Pediatrics Committee on Substance Use and Prevention, “Medication-Assisted Treatment of Adolescents With Opioid Use Disorders,” ISSN 1098-4275 (August 2016), available at <http://pediatrics.aappublications.org/content/pediatrics/early/2016/08/18/peds.2016-1893.full.pdf> (last visited April 6, 2018).

167.

World Health Organization, supra note 161.

168.

American Psychiatric Association, “Position Statement on Treatment of Substance Use Disorders in the Criminal Justice System” (December 2016).

169.

Malave

, “Note: Prison Health Care After the Affordable Care Act: Envisioning an End to the Policy of Neglect,” New York University Law Review 89 (2014): 700-738, at 730.

170.

Id. at 731.

171.

Kaiser Family Foundation, “States Reporting Medicaid coverage of Medication Assisted Treatment (MAT) Drugs,” 2017, available at <https://www.kff.org/medicaid/state-indicator/states-reporting-medicaid-coverage-of-medication-assisted-treatment-mat-drugs/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D> (last visited June 4, 2018).

172.

Volkow

et al ., “Medication-Assisted Therapies – Tackling the Opioid-Overdose Epidemic,” New England Journal of Medicine 370 (2014): 2063-2066, at 2065.

173.

Clemans-Cope

et al ., “Medicaid Coverage of Effective Treatment for Opioid Use Disorder,” Urban Institute, June 2017, available at <https://www.urban.org/sites/default/files/publication/90461/2001287_medicaid_coverage_of_effective_treatment_for_opioid_use_disorder.pdf> (last visited April 6, 2018).

174.

Id .

175.

Merica

, “Trump Declares Opioid Epidemic a National Health Emergency,” CNN, October 26, 2017, available at <http://www.cnn.com/2017/10/26/politics/donald-trump-opioid-epidemic/index.html> (last visited June 4, 2018).

176.

President’s Commission on Combating Drug Addiction and the Opioid Crisis, Final Report, Nov 1. 2017: 32, available at <https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-1-2017.pdf> (last visited April 6, 2018).

177.

United States Department of Health and Human Services, Office of the Surgeon General, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, (November 2016).

178.

National Governor’s Association, “A Compact to Fight Opioid Addiction,” (July 13, 2016), available at <https://www.nga.org/cms/news/2016/opioid-compact> (last visited April 6, 2018).

179.

National Association of Drug Court Professionals, “Resolution of the Board of Directors on the Availability of Medically Asissted Treatment (M.A.T) for Addiction in Drug Courts,” available at <https://www.nadcp.org/sites/default/files/nadcp/NADCP%20Board%20Statement%20on%20MAT.pdf> (last visited April 6, 2018); See also B. Andraka-Chris-tou, “What Is ‘Treatment’ for Opioid Addiction in Problem-Solving Courts? A Study of 20 Indiana Drug and Veterans Courts,” Stanford Journal of Civil Rights and Civil Liberties 13, (2017): 189-254, at 240.

180.

Lopez

, “There’s a Highly Successful Treatment for Opioid Addiction. But Stigma is Holding it Back,” Vox, November 15, 2017, available at <https://www.vox.com/science-and-health/2017/7/20/15937896/medication-assisted-treatment-methadone-buprenorphine-naltrexone> (last visited April 9, 2018).

181.

Donnelly

, “As Drug Overdoses Hit Record High, Trump Offers Little on Opioid Policy,” Fortune, August 8, 2017, available at <http://fortune.com/2017/08/08/record-high-drug-related-death-rate-2016/> (last visited April 9, 2018).

182.

Vestal

, “At Rikers Island, a Legacy of Medication-Assisted Opioid Treatment,” Stateline, May 23, 2016, available at <http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2016/05/23/at-rikers-island-a-legacy-of-medication-assisted-opioid-treatment> (last visited April 9, 2018).

183.

Chen and

Menard , “Medication-Assisted Treatment for Inmates: Work Group Evaluation Report and Recommendations,” Report to the Vermont Legislature (November 16, 2016), available at <https://legislature.vermont.gov/assets/Legislative-Reports/DOC-MAT-Eval-report-final.pdf> (last visited April 9, 2018); Maurer, supra note 151.

184.

Freyer

, “State Crime Bills would Expand Inmates’ Access to Addiction Treatment,” The Boston Globe, November 20, 2017, available at <https://www.bostonglobe.com/metro/2017/11/20/state-crime-bills-would-expand-inmates-access-addiction-treatment/7TI2SCOz5FNEZgmrEnIl2O/story.html> (last visited April 9, 2018).

185.

Bureau of Prisons, “Federal Prison System FY 2017 Performance Budget,” available at <https://www.justice.gov/jmd/file/821381/download> (last visited April 9, 2018).

186.

Joseph

, “One State Takes a Novel Approach to Opioid Addiction: Access to Treatment for all Inmates,” STAT News, August 3, 2017, available at <https://www.statnews.com/2017/08/03/opioid-treatment-prisons/> (last visited April 9, 2018).

187.

Office of Governor Gina

Raimondo

, “Raimondo Signs Ambitious Package of Bills Aimed at Preventing Overdoses and Saving Lives,” (July 12, 2016), available at <http://www.ri.gov/press/view/28044> (last visited April 9, 2018).

188.

Anderson ,

Pina , and

Bogdan , “Raimondo’s Midterm Grades: Campaign Promises During her first 2 Years as Governor,” The Providence Journal, February 10, 2017, available at <http://www.providencejournal.com/news/20170210/raimondos-midterm-grades-campaign-promises-during-herfirst-2-years-as-governor> (last visited April 9, 2018).

189.

Office of Governor Gina

Raimondo

, “Raimondo Moves to Tackle Opioid Crisis, Appoints Task Force,” August 4, 2015, available at <http://www.ri.gov/press/view/25501> (last visited April 9, 2018).

190.

Governor’s Overdose Prevention and Intervention Task Force, “Rhode Island’s Strategic Plan on Addiction and Overdose: Four Strategies to Alter the Course of an Epidemic,” November 4, 2015, available at <http://www.health.ri.gov/news/temp/RhodeIslandsStrategicPlanOnAddictionAndOverdose.pdf> (last visited April 9, 2018).

191.

Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database, released 2015, available at <http://wonder.cdc.gov/ucd-icd10.html> (last visited April 9, 2018); SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2012 and 2013, available at <http://www.samhsa.gov/data/sites/default/files/NSDUHStateEst2012-2013-p1/Tables/NSDUHsaePercents2013.pdf on Oct 14, 2017> (last visited April 9, 2018).

192.

G.M.

Raimondo

, “Governor’s Overdose Prevention and Intervention Task Force,” Executive Order 15-14 (August 4, 2015).

193.

Office of Governor Raimondo, supra note 189.

194.

Governor’s Overdose Prevention and Intervention Task Force, supra note 190.

195.

G.M. Raimondo, supra note 192.

196.

Governor’s Overdose Prevention and Intervention Task Force, supra note 190.

197.

Id .

198.

Id .

199.

Id .

200.

Office of Governor Raimondo, supra note 189.

201.

State of Rhode Island Office of Management and Budget, FY 2017 Interactive Budget, available at <http://www.omb.ri.gov/budget/prioryear/operating/2017.php> (last visited April 9, 2018).

202.

Joseph, supra note 186.

203.

Residential Substance Abuse Treatment (RSAT), “Prison/Jail Medication Assisted Treatment Manual,” available at <http://www.rsat-tta.com/Files/RSAT_Prison_Med_Treat_FINAL.pdf> (last visited April 9, 2018).

204.

Id .

205.

Id .

206.

RSAT, “Medication-Assisted Treatment for Justice-Involved Populations: Profiles,” available at <http://www.rsat-tta.com/Files/MAT-for-Justice-Involved-Populations---just-profiles.docx> (last visited April 9, 2018).

207.

Id .

208.

Kaeble ,

Glaze ,

Tsoutis , and

Minton , “Correctional Populations in the United States, 2014,” Bureau of Justice Statistics, December 29, 2015, available at <https://www.bjs.gov/index.cfm?ty=pbdetail&iid=5519> (last visited April 9, 2018).

209.

Substance Abuse and Mental Health Services Administration, “Buprenorphine,” available at <https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine> (last visited April 9, 2018).

210.

Author conversation with Connecticut DOC.

211.

Id .

212.

, supra note 203.

213.

Author conversation, supra note 210.

214.

Id .

215.

Joseph, supra note 186.

216.

Rhode Island Department of Corrections, “Facilities,” available at <http://www.doc.ri.gov/institutions/facilities/index.php> (last visited April 9, 2018).

217.

Rhode Island Department of Corrections, “Budget Projections for MAT program,” January 2016.

218.

Id .

219.

T. Greene et al., supra note 11, at E1.

220.

Id .

221.

See e.g., Legal Action Center, “Legality of Denying Access to Medication Assisted Treatment in the Criminal Justice System,” (2011): 1-19, at 6-17, available at <https://lac.org/wp-content/uploads/2014/12/MAT_Report_FINAL_12-1-2011.pdf> (last visited April 9, 2018).

Prisoners as Patients: The Opioid Epidemic,Medication-Assisted Treatment,and the Eighth Amendment

Abstract

Get full access to this article

References